Public dataset
Recorded source agreement and disagreement
Show whether sources print one normalized reading, have incompatible units, lack structured comparison context, or contain a context-matched numeric difference.
- Public rows
- 1,681
- Generated
- Schema version
- source-consensus/2
Coverage
What this run contains
- Compared medicine fields
- 1,681
- Agree
- 1,282
- Differ
- 0
- Not comparable
- 12
- Insufficient context
- 387
- Fields represented
- 5
- bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
Method
How the rows were made
- Deterministic rules normalize recorded pharmacokinetic readings and compare only like-for-like values.
- One normalized printed reading may be agree even when clinical context was not extracted; this reports printed-reading agreement only.
- Distinct readings may differ only when their units and denominators are comparable and one matching, non-placeholder population/formulation context was structurally extracted. Otherwise they are insufficient_context.
- not_comparable preserves incompatible units or denominators instead of guessing. insufficient_context preserves missing or non-matching structured context instead of manufacturing agreement or disagreement.
- The agreement rate describes the distribution of recorded source readings; it is not a probability that a value is true.
- Every distinct printed reading retains its unit, population context, source count, and complete source records. The API paginates field rows, never child readings or sources.
- documentsExamined is every matching single-substance archive document inspected for that medicine. The generator has no document, reading, or source ceiling, so there is no hidden available-versus-retained remainder.
Limits
Read these before using a row
- Current label parsing does not structurally extract population or formulation context. Distinct otherwise-comparable readings are therefore insufficient_context, never differ; agree may mean printed-reading agreement only. Source records are complete but are not independent-experiment counts.
- The current deterministic parser does not structurally extract population or formulation context from these sentences. It records that context as unknown and cannot publish distinct same-unit readings as differ.
- Neither reading is marked wrong. Population, formulation, route, and other unextracted context may explain the printed difference.
- Only the recorded fields and source documents in this snapshot are compared.
- A source count is the number of retained source records in the row, not a count of independent experiments.
Provenance
Source examples
abacavir · bioavailability · agree
15 documents examined; 83% (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)The geometric mean absolute bioavailability of the tablet was 83%.
alemtuzumab · volumeOfDistribution · not_comparable
2 documents examined; 0.18 L/kg (Unknown: population and formulation context were not structurally extracted from this source sentence.); 14.1 L (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:4f5f7255-7abc-4328-bd1a-ceaf139ef3e0 (opens source in a new tab)Distribution After the last 30 mg dose, the mean volume of distribution at steady-state was 0.18 L/kg (range 0.1 to 0.4 L/kg).
abiraterone · halfLife · insufficient_context
31 documents examined; 12 ± 5 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.); 18 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:c9eb9b46-f847-40a8-802c-a51b40406d5a (opens source in a new tab)Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.
Artifact used for this view: data/source-consensus.ndjson. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.
Schema
Fields in the public projection
| Field | Type | Meaning |
|---|---|---|
| medicineSlug | string | Stable RNAWiki medicine route key. |
| field | string | Recorded pharmacokinetic field being compared. |
| comparisonState | string | agree (printed-reading agreement), differ (context-matched comparable disjoint values), not_comparable (unit/denominator mismatch), or insufficient_context. Every state remains declared even when its current count is zero. |
| comparisonReasons | string[] | Deterministic codes explaining the state. |
| documentsExamined | number | Recorded source documents considered for the field. |
| sourceCount | number | Recorded source readings represented. |
| agreementRate | number | Share represented by the leading normalized printed-reading group; not a confidence score or clinical agreement probability. |
| readings | consensus-reading[] | Complete, untruncated reading groups. Each keeps the printed display, numeric value when parsed, unit, population context, source count, and every source identity, version/effective date or explicit absence, retrieval date, locator, safe link, and excerpt. |
Reader
Search and filter the rows
Showing 821–830 of 1,681 matching rows. Filters and search terms remain attached when you move between pages or open the API view.
Projected row 821
- Medicine slug
- lanreotide
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 4
- Source count
- 4
- Agreement rate
- 1
- Recorded readings
23 to 30 days
- Numeric value
- Not parsed
- Unit
- Not recorded
- Source records
- 4
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 4 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:11da176a-99bc-4ada-8b3f-6bd2b37a6313 (opens source in a new tab)
Lanreotide label
Version not recorded · Effective date not recorded
Lanreotide showed sustained release of lanreotide with a half-life of 23 to 30 days.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2892b4c3-0329-4d29-97ff-3b45283bbab1 (opens source in a new tab)
Lanreotide label
Version not recorded · Effective date not recorded
Lanreotide acetate showed sustained release of lanreotide with a half-life of 23 to 30 days.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6e4a41fd-a753-4362-87ee-8cc56ed3660d (opens source in a new tab)
Lanreotide label
Version not recorded · Effective date not recorded
SOMATULINE DEPOT showed sustained release of lanreotide with a half-life of 23 to 30 days.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:eec3c37e-83a7-4195-bccf-cd5973459eef (opens source in a new tab)
Lanreotide label
Version not recorded · Effective date not recorded
Lanreotide acetate showed sustained release of lanreotide with a half-life of 23 to 30 days.
Projected row 822
- Medicine slug
- lansoprazole
- Compared field
- bioavailability
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 102
- Source count
- 61
- Agreement rate
- 1
- Recorded readings
80%
- Numeric value
- 80
- Unit
- %
- Source records
- 61
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 61 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9e246e79-2737-4cbb-ad5d-4e76893da3be (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
The absolute bioavailability is over 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:33fc642c-ad41-410b-9a81-eae456f3fcfb (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
The absolute bioavailability is over 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:03b7dceb-2128-4324-b068-7f76a2d9887e (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
The absolute bioavailability is over 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7d811f01-f0c2-4753-bb36-80b48dabb58c (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Absorption: The absorption of lansoprazole is rapid, with the mean C max occurring approximately 1.7 hours after oral dosing, and the absolute bioavailability is over 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6d81faf7-aa59-429c-e053-2a91aa0a8bb2 (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Absorption: The absorption of lansoprazole is rapid, with the mean C max occurring approximately 1.7 hours after oral dosing, and the absolute bioavailability is over 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dee80a19-e514-41e6-9153-c959699d97b1 (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
The absolute bioavailability is over 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:656bc92a-1f95-047d-cd27-724073e63fe6 (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
The absolute bioavailability is over 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:71ba78cb-7e46-43eb-9425-fa130f537f84 (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
The absolute bioavailability is over 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dfdc9aa0-8612-9127-e053-2a95a90ae7c8 (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
The absolute bioavailability is over 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9b3869ad-f2f7-4954-b75c-5c23b8951635 (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
The absolute bioavailability is over 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a612a237-ec17-49f0-8985-44407608adb5 (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
The absolute bioavailability is over 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ce1a4f32-da65-29d3-e053-2995a90a42ee (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
The absolute bioavailability is over 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1bbb8f3a-80bf-b881-e063-6294a90ab4f2 (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
The absolute bioavailability is over 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:960d6601-aec5-4900-a400-385b6687a4bc (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
The absolute bioavailability is over 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:18b4020f-d7e6-42f8-838d-2b5da152530e (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
The absolute bioavailability is over 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ac051296-6fe3-4ab5-a001-cc3e06199a22 (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
The absolute bioavailability is over 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:427cf924-be17-47dc-8f77-115fa2f3fe17 (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
The absolute bioavailability is over 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:db42468a-450c-4b12-b2f2-e9a76e976d45 (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
The absolute bioavailability is over 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7286d6a5-611b-4993-ab93-4899d599435d (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
The absolute bioavailability is over 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:22f416bf-00f1-ceb9-e063-6394a90aa1dd (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
The absolute bioavailability is over 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b12cca1c-da28-67e2-e053-2a95a90aaf6b (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
The absolute bioavailability is over 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:136ad992-2e39-dad9-e063-6294a90adcc6 (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
The absolute bioavailability is over 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e07c7445-9652-4833-8b17-45c0124c4e5d (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
The absolute bioavailability is over 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4c7cc078-09de-f4fc-d111-1248f2261d17 (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
The absolute bioavailability is over 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7a79feee-2e21-4cd0-a720-c59643764303 (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
The absolute bioavailability is over 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8bbc3af5-faa1-4af1-94e9-9df4aae242ab (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
The absolute bioavailability is over 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:00a574e0-bd03-deea-9f85-b108f78982ba (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
The absolute bioavailability is over 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ae03d05b-0a0f-4bae-bbdc-450b7b5f7a92 (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
The absolute bioavailability is over 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9a277b9e-2e13-27c3-e053-2995a90a7ed5 (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
The absolute bioavailability is over 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:37b221ee-b6a4-76e8-e063-6394a90a7e0b (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
The absolute bioavailability is over 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:71be1129-8562-476e-9d9b-99a21cbf52ec (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
The absolute bioavailability is over 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1c364fc5-eb43-b12f-e063-6294a90a4319 (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
The absolute bioavailability is over 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:551ae468-1a2d-43d6-a2a8-4e5f26e0f982 (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
The absolute bioavailability is over 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:12b2e59b-2b7a-4d22-ad9b-9a7d9a5264bd (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
The absolute bioavailability is over 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:82174fcc-1b0f-2068-7fc4-db335b43b5e2 (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
The absolute bioavailability is over 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1dc026b6-b521-4a46-9a74-8c1c140d5329 (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
The absolute bioavailability is over 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:16dc1e02-4679-4d7f-a65b-6e3706655d35 (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
The absolute bioavailability is over 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:afcc0f14-8b00-41ac-8e62-4094a15b959c (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
The absolute bioavailability is over 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a9dd7e56-1aee-5f0b-e053-2995a90a43bf (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
The absolute bioavailability is over 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:eea82d0b-6600-4693-a2b8-596a55458f61 (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
The absolute bioavailability is over 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e7a3aa37-9c9b-43fe-92be-6e0fdc8d1c92 (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
The absolute bioavailability is over 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:924c5a35-4804-4e14-a2fc-2b84d186d257 (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
The absolute bioavailability is over 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:20ff347c-ca18-497b-948d-1145035f2ffc (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
The absolute bioavailability is over 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8f0d3f2f-91d9-467a-a841-540664af80f9 (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
The absolute bioavailability is over 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c8fa7401-907f-41b6-a2e1-f4bc214f2cdf (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
The absolute bioavailability is over 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:75691c2d-2265-4153-bc3a-4f7d5d51e250 (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
The absolute bioavailability is over 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cc006372-32d3-4539-921a-6bc9ec496b28 (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
The absolute bioavailability is over 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e0299cf2-8a8e-499b-a81e-16e844ea3aff (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
The absolute bioavailability is over 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:495d3ca8-d37d-440a-80ce-9342d9ff281a (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
The absolute bioavailability is over 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3e3e63df-e2ad-420b-acb9-28e65ea6fb07 (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Absorption: The absorption of lansoprazole is rapid, with the mean C max occurring approximately 1.7 hours after oral dosing, and the absolute bioavailability is over 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:44f07613-35be-4673-98f0-4b2467acce9c (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
The absolute bioavailability is over 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c77da981-9260-fabd-e053-2a95a90aa71c (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
The absolute bioavailability is over 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:56cafcf5-ce3d-a312-e063-6294a90a3db1 (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
The absolute bioavailability is over 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:11344047-7ed4-61e7-e063-6394a90a332d (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
The absolute bioavailability is over 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3babf7d9-ad83-4e44-8e5d-f6c11b2d76b6 (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
The absolute bioavailability is over 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c9a43df0-efab-4486-860f-92afdb258c8b (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
The absolute bioavailability is over 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:47a8618c-e768-41bf-9116-634b564405d4 (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
The absolute bioavailability is over 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1f2883d8-12db-40b7-9104-22a6690a22a7 (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
The absolute bioavailability is over 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6b8dd0e1-cd69-4f9a-887f-e42627b5d78e (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
The absolute bioavailability is over 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6b9c60e9-b0d2-4aec-a04b-ccc7a62c822b (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
The absolute bioavailability is over 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:854e4235-4815-4461-9b9b-d3d783fb775d (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
The absolute bioavailability is over 80%.
Projected row 823
- Medicine slug
- lansoprazole
- Compared field
- halfLife
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 102
- Source count
- 61
- Agreement rate
- 0.95082
- Recorded readings
1.9 to 2.9 hours
- Numeric value
- 1.9
- Unit
- hours
- Source records
- 58
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 58 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9e246e79-2737-4cbb-ad5d-4e76893da3be (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Because the mean half-life in the elderly remains between 1.9 to 2.9 hours, repeated once daily dosing does not result in accumulation of lansoprazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:33fc642c-ad41-410b-9a81-eae456f3fcfb (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Because the mean half-life in the elderly remains between 1.9 to 2.9 hours, repeated once daily dosing does not result in accumulation of lansoprazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:03b7dceb-2128-4324-b068-7f76a2d9887e (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Because the mean half-life in the elderly remains between 1.9 to 2.9 hours, repeated once daily dosing does not result in accumulation of lansoprazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dee80a19-e514-41e6-9153-c959699d97b1 (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Because the mean half-life in the elderly remains between 1.9 to 2.9 hours, repeated once daily dosing does not result in accumulation of lansoprazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:656bc92a-1f95-047d-cd27-724073e63fe6 (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Because the mean half-life in the elderly remains between 1.9 to 2.9 hours, repeated once daily dosing does not result in accumulation of lansoprazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:71ba78cb-7e46-43eb-9425-fa130f537f84 (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Because the mean half-life in the elderly remains between 1.9 to 2.9 hours, repeated once daily dosing does not result in accumulation of lansoprazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dfdc9aa0-8612-9127-e053-2a95a90ae7c8 (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Because the mean half-life in the elderly remains between 1.9 to 2.9 hours, repeated once daily dosing does not result in accumulation of lansoprazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9b3869ad-f2f7-4954-b75c-5c23b8951635 (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Because the mean half-life in the elderly remains between 1.9 to 2.9 hours, repeated once daily dosing does not result in accumulation of lansoprazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a612a237-ec17-49f0-8985-44407608adb5 (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Because the mean half-life in the elderly remains between 1.9 to 2.9 hours, repeated once daily dosing does not result in accumulation of lansoprazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ce1a4f32-da65-29d3-e053-2995a90a42ee (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Because the mean half-life in the elderly remains between 1.9 to 2.9 hours, repeated once daily dosing does not result in accumulation of lansoprazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1bbb8f3a-80bf-b881-e063-6294a90ab4f2 (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Because the mean half-life in the elderly remains between 1.9 to 2.9 hours, repeated once daily dosing does not result in accumulation of lansoprazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:960d6601-aec5-4900-a400-385b6687a4bc (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Because the mean half-life in the elderly remains between 1.9 to 2.9 hours, repeated once daily dosing does not result in accumulation of lansoprazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:18b4020f-d7e6-42f8-838d-2b5da152530e (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Because the mean half-life in the elderly remains between 1.9 to 2.9 hours, repeated once daily dosing does not result in accumulation of lansoprazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ac051296-6fe3-4ab5-a001-cc3e06199a22 (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Because the mean half-life in the elderly remains between 1.9 to 2.9 hours, repeated once daily dosing does not result in accumulation of lansoprazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:427cf924-be17-47dc-8f77-115fa2f3fe17 (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Because the mean half-life in the elderly remains between 1.9 to 2.9 hours, repeated once daily dosing does not result in accumulation of lansoprazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:db42468a-450c-4b12-b2f2-e9a76e976d45 (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Because the mean half-life in the elderly remains between 1.9 to 2.9 hours, repeated once daily dosing does not result in accumulation of lansoprazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7286d6a5-611b-4993-ab93-4899d599435d (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Because the mean half-life in the elderly remains between 1.9 to 2.9 hours, repeated once daily dosing does not result in accumulation of lansoprazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:22f416bf-00f1-ceb9-e063-6394a90aa1dd (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Because the mean half-life in the elderly remains between 1.9 to 2.9 hours, repeated once daily dosing does not result in accumulation of lansoprazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b12cca1c-da28-67e2-e053-2a95a90aaf6b (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Because the mean half-life in the elderly remains between 1.9 to 2.9 hours, repeated once daily dosing does not result in accumulation of lansoprazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:136ad992-2e39-dad9-e063-6294a90adcc6 (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Because the mean half-life in the elderly remains between 1.9 to 2.9 hours, repeated once daily dosing does not result in accumulation of lansoprazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e07c7445-9652-4833-8b17-45c0124c4e5d (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Because the mean half-life in the elderly remains between 1.9 to 2.9 hours, repeated once daily dosing does not result in accumulation of lansoprazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4c7cc078-09de-f4fc-d111-1248f2261d17 (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Because the mean half-life in the elderly remains between 1.9 to 2.9 hours, repeated once daily dosing does not result in accumulation of lansoprazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7a79feee-2e21-4cd0-a720-c59643764303 (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Because the mean half-life in the elderly remains between 1.9 to 2.9 hours, repeated once daily dosing does not result in accumulation of lansoprazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8bbc3af5-faa1-4af1-94e9-9df4aae242ab (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Because the mean half-life in the elderly remains between 1.9 to 2.9 hours, repeated once daily dosing does not result in accumulation of lansoprazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:00a574e0-bd03-deea-9f85-b108f78982ba (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Because the mean half-life in the elderly remains between 1.9 to 2.9 hours, repeated once daily dosing does not result in accumulation of lansoprazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ae03d05b-0a0f-4bae-bbdc-450b7b5f7a92 (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Because the mean half-life in the elderly remains between 1.9 to 2.9 hours, repeated once daily dosing does not result in accumulation of lansoprazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9a277b9e-2e13-27c3-e053-2995a90a7ed5 (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Because the mean half-life in the elderly remains between 1.9 to 2.9 hours, repeated once daily dosing does not result in accumulation of lansoprazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:37b221ee-b6a4-76e8-e063-6394a90a7e0b (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Because the mean half-life in the elderly remains between 1.9 to 2.9 hours, repeated once daily dosing does not result in accumulation of lansoprazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:71be1129-8562-476e-9d9b-99a21cbf52ec (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Because the mean half-life in the elderly remains between 1.9 to 2.9 hours, repeated once daily dosing does not result in accumulation of lansoprazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1c364fc5-eb43-b12f-e063-6294a90a4319 (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Because the mean half-life in the elderly remains between 1.9 to 2.9 hours, repeated once daily dosing does not result in accumulation of lansoprazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:551ae468-1a2d-43d6-a2a8-4e5f26e0f982 (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Because the mean half-life in the elderly remains between 1.9 to 2.9 hours, repeated once daily dosing does not result in accumulation of lansoprazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:12b2e59b-2b7a-4d22-ad9b-9a7d9a5264bd (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Because the mean half-life in the elderly remains between 1.9 to 2.9 hours, repeated once daily dosing does not result in accumulation of lansoprazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:82174fcc-1b0f-2068-7fc4-db335b43b5e2 (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Because the mean half-life in the elderly remains between 1.9 to 2.9 hours, repeated once daily dosing does not result in accumulation of lansoprazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1dc026b6-b521-4a46-9a74-8c1c140d5329 (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Because the mean half-life in the elderly remains between 1.9 to 2.9 hours, repeated once daily dosing does not result in accumulation of lansoprazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:16dc1e02-4679-4d7f-a65b-6e3706655d35 (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Because the mean half-life in the elderly remains between 1.9 to 2.9 hours, repeated once daily dosing does not result in accumulation of lansoprazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:afcc0f14-8b00-41ac-8e62-4094a15b959c (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Because the mean half-life in the elderly remains between 1.9 to 2.9 hours, repeated once daily dosing does not result in accumulation of lansoprazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a9dd7e56-1aee-5f0b-e053-2995a90a43bf (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Because the mean half-life in the elderly remains between 1.9 to 2.9 hours, repeated once daily dosing does not result in accumulation of lansoprazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:eea82d0b-6600-4693-a2b8-596a55458f61 (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Because the mean half-life in the elderly remains between 1.9 to 2.9 hours, repeated once daily dosing does not result in accumulation of lansoprazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e7a3aa37-9c9b-43fe-92be-6e0fdc8d1c92 (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Because the mean half-life in the elderly remains between 1.9 to 2.9 hours, repeated once daily dosing does not result in accumulation of lansoprazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:924c5a35-4804-4e14-a2fc-2b84d186d257 (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Because the mean half-life in the elderly remains between 1.9 to 2.9 hours, repeated once daily dosing does not result in accumulation of lansoprazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:20ff347c-ca18-497b-948d-1145035f2ffc (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Because the mean half-life in the elderly remains between 1.9 to 2.9 hours, repeated once daily dosing does not result in accumulation of lansoprazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8f0d3f2f-91d9-467a-a841-540664af80f9 (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Because the mean half-life in the elderly remains between 1.9 to 2.9 hours, repeated once daily dosing does not result in accumulation of lansoprazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c8fa7401-907f-41b6-a2e1-f4bc214f2cdf (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Because the mean half-life in the elderly remains between 1.9 to 2.9 hours, repeated once daily dosing does not result in accumulation of lansoprazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:75691c2d-2265-4153-bc3a-4f7d5d51e250 (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Because the mean half-life in the elderly remains between 1.9 to 2.9 hours, repeated once daily dosing does not result in accumulation of lansoprazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cc006372-32d3-4539-921a-6bc9ec496b28 (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Because the mean half-life in the elderly remains between 1.9 to 2.9 hours, repeated once daily dosing does not result in accumulation of lansoprazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e0299cf2-8a8e-499b-a81e-16e844ea3aff (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Because the mean half-life in the elderly remains between 1.9 to 2.9 hours, repeated once daily dosing does not result in accumulation of lansoprazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:495d3ca8-d37d-440a-80ce-9342d9ff281a (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Because the mean half-life in the elderly remains between 1.9 to 2.9 hours, repeated once daily dosing does not result in accumulation of lansoprazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:44f07613-35be-4673-98f0-4b2467acce9c (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Because the mean half-life in the elderly remains between 1.9 to 2.9 hours, repeated once daily dosing does not result in accumulation of lansoprazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c77da981-9260-fabd-e053-2a95a90aa71c (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Because the mean half-life in the elderly remains between 1.9 to 2.9 hours, repeated once daily dosing does not result in accumulation of lansoprazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:56cafcf5-ce3d-a312-e063-6294a90a3db1 (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Because the mean half-life in the elderly remains between 1.9 to 2.9 hours, repeated once daily dosing does not result in accumulation of lansoprazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:11344047-7ed4-61e7-e063-6394a90a332d (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Because the mean half-life in the elderly remains between 1.9 to 2.9 hours, repeated once daily dosing does not result in accumulation of lansoprazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3babf7d9-ad83-4e44-8e5d-f6c11b2d76b6 (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Because the mean half-life in the elderly remains between 1.9 to 2.9 hours, repeated once daily dosing does not result in accumulation of lansoprazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c9a43df0-efab-4486-860f-92afdb258c8b (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Because the mean half-life in the elderly remains between 1.9 to 2.9 hours, repeated once daily dosing does not result in accumulation of lansoprazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:47a8618c-e768-41bf-9116-634b564405d4 (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Because the mean half-life in the elderly remains between 1.9 to 2.9 hours, repeated once daily dosing does not result in accumulation of lansoprazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1f2883d8-12db-40b7-9104-22a6690a22a7 (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Because the mean half-life in the elderly remains between 1.9 to 2.9 hours, repeated once daily dosing does not result in accumulation of lansoprazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6b8dd0e1-cd69-4f9a-887f-e42627b5d78e (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Because the mean half-life in the elderly remains between 1.9 to 2.9 hours, repeated once daily dosing does not result in accumulation of lansoprazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6b9c60e9-b0d2-4aec-a04b-ccc7a62c822b (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Because the mean half-life in the elderly remains between 1.9 to 2.9 hours, repeated once daily dosing does not result in accumulation of lansoprazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:854e4235-4815-4461-9b9b-d3d783fb775d (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Because the mean half-life in the elderly remains between 1.9 to 2.9 hours, repeated once daily dosing does not result in accumulation of lansoprazole.
2 hours
- Numeric value
- 2
- Unit
- hours
- Source records
- 3
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 3 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7d811f01-f0c2-4753-bb36-80b48dabb58c (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
The plasma elimination half-life of lansoprazole is less than 2 hours while the acid inhibitory effect lasts more than 24 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6d81faf7-aa59-429c-e053-2a91aa0a8bb2 (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
The plasma elimination half-life of lansoprazole is less than 2 hours while the acid inhibitory effect lasts more than 24 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3e3e63df-e2ad-420b-acb9-28e65ea6fb07 (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
The plasma elimination half-life of lansoprazole is less than 2 hours while the acid inhibitory effect lasts more than 24 hours.
Projected row 824
- Medicine slug
- lansoprazole
- Compared field
- proteinBinding
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 102
- Source count
- 61
- Agreement rate
- 0.754098
- Recorded readings
1 to 1.5%
- Numeric value
- 1
- Unit
- %
- Source records
- 46
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 46 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9e246e79-2737-4cbb-ad5d-4e76893da3be (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Patients with Renal Impairment: In patients with severe renal impairment, plasma protein binding decreased by 1 to 1.5% after administration of 60 mg of lansoprazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:33fc642c-ad41-410b-9a81-eae456f3fcfb (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Patients with Renal Impairment: In patients with severe renal impairment, plasma protein binding decreased by 1 to 1.5% after administration of 60 mg of lansoprazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:03b7dceb-2128-4324-b068-7f76a2d9887e (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Patients with Renal Impairment: In patients with severe renal impairment, plasma protein binding decreased by 1 to 1.5% after administration of 60 mg of lansoprazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dee80a19-e514-41e6-9153-c959699d97b1 (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Patients with Renal Impairment: In patients with severe renal impairment, plasma protein binding decreased by 1 to 1.5% after administration of 60 mg of lansoprazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:656bc92a-1f95-047d-cd27-724073e63fe6 (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Patients with Renal Impairment: In patients with severe renal impairment, plasma protein binding decreased by 1 to 1.5% after administration of 60 mg of lansoprazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:71ba78cb-7e46-43eb-9425-fa130f537f84 (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Patients with Renal Impairment: In patients with severe renal impairment, plasma protein binding decreased by 1 to 1.5% after administration of 60 mg of lansoprazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dfdc9aa0-8612-9127-e053-2a95a90ae7c8 (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Patients with Renal Impairment: In patients with severe renal impairment, plasma protein binding decreased by 1 to 1.5% after administration of 60 mg of lansoprazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9b3869ad-f2f7-4954-b75c-5c23b8951635 (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Patients with Renal Impairment: In patients with severe renal impairment, plasma protein binding decreased by 1 to 1.5% after administration of 60 mg of lansoprazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ce1a4f32-da65-29d3-e053-2995a90a42ee (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Patients with Renal Impairment: In patients with severe renal impairment, plasma protein binding decreased by 1 to 1.5% after administration of 60 mg of lansoprazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1bbb8f3a-80bf-b881-e063-6294a90ab4f2 (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Patients with Renal Impairment: In patients with severe renal impairment, plasma protein binding decreased by 1 to 1.5% after administration of 60 mg of lansoprazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:960d6601-aec5-4900-a400-385b6687a4bc (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Patients with Renal Impairment: In patients with severe renal impairment, plasma protein binding decreased by 1 to 1.5% after administration of 60 mg of lansoprazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:18b4020f-d7e6-42f8-838d-2b5da152530e (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Patients with Renal Impairment: In patients with severe renal impairment, plasma protein binding decreased by 1 to 1.5% after administration of 60 mg of lansoprazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ac051296-6fe3-4ab5-a001-cc3e06199a22 (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Patients with Renal Impairment: In patients with severe renal impairment, plasma protein binding decreased by 1 to 1.5% after administration of 60 mg of lansoprazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:427cf924-be17-47dc-8f77-115fa2f3fe17 (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Patients with Renal Impairment: In patients with severe renal impairment, plasma protein binding decreased by 1 to 1.5% after administration of 60 mg of lansoprazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7286d6a5-611b-4993-ab93-4899d599435d (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Patients with Renal Impairment: In patients with severe renal impairment, plasma protein binding decreased by 1 to 1.5% after administration of 60 mg of lansoprazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:22f416bf-00f1-ceb9-e063-6394a90aa1dd (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Patients with Renal Impairment: In patients with severe renal impairment, plasma protein binding decreased by 1 to 1.5% after administration of 60 mg of lansoprazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b12cca1c-da28-67e2-e053-2a95a90aaf6b (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Patients with Renal Impairment: In patients with severe renal impairment, plasma protein binding decreased by 1 to 1.5% after administration of 60 mg of lansoprazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:136ad992-2e39-dad9-e063-6294a90adcc6 (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Patients with Renal Impairment: In patients with severe renal impairment, plasma protein binding decreased by 1 to 1.5% after administration of 60 mg of lansoprazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e07c7445-9652-4833-8b17-45c0124c4e5d (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Patients with Renal Impairment: In patients with severe renal impairment, plasma protein binding decreased by 1 to 1.5% after administration of 60 mg of lansoprazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4c7cc078-09de-f4fc-d111-1248f2261d17 (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Patients with Renal Impairment: In patients with severe renal impairment, plasma protein binding decreased by 1 to 1.5% after administration of 60 mg of lansoprazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7a79feee-2e21-4cd0-a720-c59643764303 (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Patients with Renal Impairment In patients with severe renal impairment, plasma protein binding decreased by 1 to 1.5% after administration of 60 mg of lansoprazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8bbc3af5-faa1-4af1-94e9-9df4aae242ab (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Patients with Renal Impairment: In patients with severe renal impairment, plasma protein binding decreased by 1 to 1.5% after administration of 60 mg of lansoprazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9a277b9e-2e13-27c3-e053-2995a90a7ed5 (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Patients with Renal Impairment: In patients with severe renal impairment, plasma protein binding decreased by 1 to 1.5% after administration of 60 mg of lansoprazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:71be1129-8562-476e-9d9b-99a21cbf52ec (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Patients with Renal Impairment: In patients with severe renal impairment, plasma protein binding decreased by 1 to 1.5% after administration of 60 mg of lansoprazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1c364fc5-eb43-b12f-e063-6294a90a4319 (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Patients with Renal Impairment: In patients with severe renal impairment, plasma protein binding decreased by 1 to 1.5% after administration of 60 mg of lansoprazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:551ae468-1a2d-43d6-a2a8-4e5f26e0f982 (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Patients with Renal Impairment: In patients with severe renal impairment, plasma protein binding decreased by 1 to 1.5% after administration of 60 mg of lansoprazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:12b2e59b-2b7a-4d22-ad9b-9a7d9a5264bd (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Patients with Renal Impairment: In patients with severe renal impairment, plasma protein binding decreased by 1 to 1.5% after administration of 60 mg of lansoprazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:82174fcc-1b0f-2068-7fc4-db335b43b5e2 (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Patients with Renal Impairment: In patients with severe renal impairment, plasma protein binding decreased by 1 to 1.5% after administration of 60 mg of lansoprazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:afcc0f14-8b00-41ac-8e62-4094a15b959c (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Patients with Renal Impairment: In patients with severe renal impairment, plasma protein binding decreased by 1 to 1.5% after administration of 60 mg of lansoprazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:eea82d0b-6600-4693-a2b8-596a55458f61 (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Patients with Renal Impairment In patients with severe renal impairment, plasma protein binding decreased by 1 to 1.5% after administration of 60 mg of lansoprazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e7a3aa37-9c9b-43fe-92be-6e0fdc8d1c92 (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Patients with Renal Impairment: In patients with severe renal impairment, plasma protein binding decreased by 1 to 1.5% after administration of 60 mg of lansoprazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:924c5a35-4804-4e14-a2fc-2b84d186d257 (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Patients with Renal Impairment : In patients with severe renal impairment, plasma protein binding decreased by 1 to 1.5% after administration of 60 mg of lansoprazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:20ff347c-ca18-497b-948d-1145035f2ffc (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Patients with Renal Impairment In patients with severe renal impairment, plasma protein binding decreased by 1 to 1.5% after administration of 60 mg of lansoprazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8f0d3f2f-91d9-467a-a841-540664af80f9 (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Patients with Renal Impairment: In patients with severe renal impairment, plasma protein binding decreased by 1 to 1.5% after administration of 60 mg of lansoprazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c8fa7401-907f-41b6-a2e1-f4bc214f2cdf (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Patients with Renal Impairment In patients with severe renal impairment, plasma protein binding decreased by 1 to 1.5% after administration of 60 mg of lansoprazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:75691c2d-2265-4153-bc3a-4f7d5d51e250 (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Patients with Renal Impairment: In patients with severe renal impairment, plasma protein binding decreased by 1 to 1.5% after administration of 60 mg of lansoprazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cc006372-32d3-4539-921a-6bc9ec496b28 (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Patients with Renal Impairment: In patients with severe renal impairment, plasma protein binding decreased by 1 to 1.5% after administration of 60 mg of lansoprazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:495d3ca8-d37d-440a-80ce-9342d9ff281a (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Patients with Renal Impairment: In patients with severe renal impairment, plasma protein binding decreased by 1 to 1.5% after administration of 60 mg of lansoprazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c77da981-9260-fabd-e053-2a95a90aa71c (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Patients with Renal Impairment: In patients with severe renal impairment, plasma protein binding decreased by 1 to 1.5% after administration of 60 mg of lansoprazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:56cafcf5-ce3d-a312-e063-6294a90a3db1 (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Patients with Renal Impairment: In patients with severe renal impairment, plasma protein binding decreased by 1 to 1.5% after administration of 60 mg of lansoprazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c9a43df0-efab-4486-860f-92afdb258c8b (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Patients with Renal Impairment: In patients with severe renal impairment, plasma protein binding decreased by 1 to 1.5% after administration of 60 mg of lansoprazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:47a8618c-e768-41bf-9116-634b564405d4 (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Patients with Renal Impairment In patients with severe renal impairment, plasma protein binding decreased by 1 to 1.5% after administration of 60 mg of lansoprazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1f2883d8-12db-40b7-9104-22a6690a22a7 (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Patients with Renal Impairment: In patients with severe renal impairment, plasma protein binding decreased by 1 to 1.5% after administration of 60 mg of lansoprazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6b8dd0e1-cd69-4f9a-887f-e42627b5d78e (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Patients with Renal Impairment: In patients with severe renal impairment, plasma protein binding decreased by 1 to 1.5% after administration of 60 mg of lansoprazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6b9c60e9-b0d2-4aec-a04b-ccc7a62c822b (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Patients with Renal Impairment: In patients with severe renal impairment, plasma protein binding decreased by 1 to 1.5% after administration of 60 mg of lansoprazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:854e4235-4815-4461-9b9b-d3d783fb775d (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Patients with Renal Impairment: In patients with severe renal impairment, plasma protein binding decreased by 1 to 1.5% after administration of 60 mg of lansoprazole.
1.0%
- Numeric value
- 1
- Unit
- %
- Source records
- 12
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 12 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a612a237-ec17-49f0-8985-44407608adb5 (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Patients with Renal Impairment: In patients with severe renal impairment, plasma protein binding decreased by 1.0% to 1.5% after administration of 60 mg of lansoprazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:db42468a-450c-4b12-b2f2-e9a76e976d45 (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Patients with Renal Impairment: In patients with severe renal impairment, plasma protein binding decreased by 1.0% to 1.5% after administration of 60 mg of lansoprazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:00a574e0-bd03-deea-9f85-b108f78982ba (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Patients with Renal Impairment: In patients with severe renal impairment, plasma protein binding decreased by 1.0% to 1.5% after administration of 60 mg of lansoprazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ae03d05b-0a0f-4bae-bbdc-450b7b5f7a92 (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Patients with Renal Impairment: In patients with severe renal impairment, plasma protein binding decreased by 1.0% to 1.5% after administration of 60 mg of lansoprazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:37b221ee-b6a4-76e8-e063-6394a90a7e0b (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Patients with Renal Impairment: In patients with severe renal impairment, plasma protein binding decreased by 1.0% to 1.5% after administration of 60 mg of lansoprazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1dc026b6-b521-4a46-9a74-8c1c140d5329 (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Patients with Renal Impairment: In patients with severe renal impairment, plasma protein binding decreased by 1.0% to 1.5% after administration of 60 mg of lansoprazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:16dc1e02-4679-4d7f-a65b-6e3706655d35 (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Patients with Renal Impairment: In patients with severe renal impairment, plasma protein binding decreased by 1.0% to 1.5% after administration of 60 mg of lansoprazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a9dd7e56-1aee-5f0b-e053-2995a90a43bf (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Patients with Renal Impairment: In patients with severe renal impairment, plasma protein binding decreased by 1.0% to 1.5% after administration of 60 mg of lansoprazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e0299cf2-8a8e-499b-a81e-16e844ea3aff (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Patients with Renal Impairment: In patients with severe renal impairment, plasma protein binding decreased by 1.0% to 1.5% after administration of 60 mg of lansoprazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:44f07613-35be-4673-98f0-4b2467acce9c (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Patients with Renal Impairment: In patients with severe renal impairment, plasma protein binding decreased by 1.0% to 1.5% after administration of 60 mg of lansoprazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:11344047-7ed4-61e7-e063-6394a90a332d (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Patients with Renal Impairment: In patients with severe renal impairment, plasma protein binding decreased by 1.0% to 1.5% after administration of 60 mg of lansoprazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3babf7d9-ad83-4e44-8e5d-f6c11b2d76b6 (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Patients with Renal Impairment: In patients with severe renal impairment, plasma protein binding decreased by 1.0% to 1.5% after administration of 60 mg of lansoprazole.
1%
- Numeric value
- 1
- Unit
- %
- Source records
- 3
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 3 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7d811f01-f0c2-4753-bb36-80b48dabb58c (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Renal Impairment: In patients with severe renal impairment, plasma protein binding decreased by 1% to 1.5% after administration of 60 mg of lansoprazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6d81faf7-aa59-429c-e053-2a91aa0a8bb2 (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Renal Impairment: In patients with severe renal impairment, plasma protein binding decreased by 1% to 1.5% after administration of 60 mg of lansoprazole.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3e3e63df-e2ad-420b-acb9-28e65ea6fb07 (opens source in a new tab)
Lansoprazole label
Version not recorded · Effective date not recorded
Renal Impairment: In patients with severe renal impairment, plasma protein binding decreased by 1% to 1.5% after administration of 60 mg of lansoprazole.
Projected row 825
- Medicine slug
- lanthanum-carbonate
- Compared field
- bioavailability
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 7
- Source count
- 7
- Agreement rate
- 1
- Recorded readings
0.002%
- Numeric value
- 0.002
- Unit
- %
- Source records
- 7
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 7 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:22b07167-2b7b-42ba-9ae9-cf58c98a2ab2 (opens source in a new tab)
Lanthanum Carbonate label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption and Distribution -Following single-or multiple-dose oral administration of lanthanum carbonate to healthy subjects, the concentration of lanthanum in plasma was very low (bioavailability <0.002%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:91556a42-5e16-4f86-bae9-a8cdd6b182a6 (opens source in a new tab)
Lanthanum Carbonate label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption and Distribution -Following single- or multiple-dose oral administration of lanthanum carbonate chewable tablets to healthy subjects, the concentration of lanthanum in plasma was very low (bioavailability <0.002%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1d5ff930-1189-4e96-bdfb-9fd9c2c83d1b (opens source in a new tab)
Lanthanum Carbonate label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption and Distribution - Following single- or multiple- dose oral administration of lanthanum carbonate to healthy subjects, the concentration of lanthanum in plasma was very low (bioavailability <0.002%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e4b88992-ecb0-455b-b68c-5c4e6d3cf521 (opens source in a new tab)
Lanthanum Carbonate label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption and Distribution - Following single- or multiple-dose oral administration of lanthanum carbonate chewable tablets to healthy subjects, the concentration of lanthanum in plasma was very low (bioavailability <0.002%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bb263fe8-2bdf-4dba-807f-194f54a73654 (opens source in a new tab)
Lanthanum Carbonate label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption and Distribution - Following single- or multiple-dose oral administration of LANTHANUM CARBONATE to healthy subjects, the concentration of lanthanum in plasma was very low (bioavailability <0.002%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:16b0e6f5-4fc9-448c-994a-cb9dd8b03654 (opens source in a new tab)
Lanthanum Carbonate label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption and Distribution - Following single- or multiple- dose oral administration of lanthanum carbonate to healthy subjects, the concentration of lanthanum in plasma was very low (bioavailability <0.002%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f10776b2-2c25-4343-aabe-68f302e5cb54 (opens source in a new tab)
Lanthanum Carbonate label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption and Distribution - Following single- or multiple-dose oral administration of FOSRENOL to healthy subjects, the concentration of lanthanum in plasma was very low (bioavailability <0.002%).
Projected row 826
- Medicine slug
- lanthanum-carbonate
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 7
- Source count
- 7
- Agreement rate
- 1
- Recorded readings
53 hours
- Numeric value
- 53
- Unit
- hours
- Source records
- 7
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 7 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:22b07167-2b7b-42ba-9ae9-cf58c98a2ab2 (opens source in a new tab)
Lanthanum Carbonate label
Version not recorded · Effective date not recorded
Lanthanum was cleared from plasma of patients undergoing dialysis with an elimination half-life of 53 hours following discontinuation of therapy.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:91556a42-5e16-4f86-bae9-a8cdd6b182a6 (opens source in a new tab)
Lanthanum Carbonate label
Version not recorded · Effective date not recorded
Lanthanum was cleared from plasma of patients undergoing dialysis with an elimination half-life of 53 hours following discontinuation of therapy.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1d5ff930-1189-4e96-bdfb-9fd9c2c83d1b (opens source in a new tab)
Lanthanum Carbonate label
Version not recorded · Effective date not recorded
Lanthanum was cleared from plasma of patients undergoing dialysis with an elimination half-life of 53 hours following discontinuation of therapy.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e4b88992-ecb0-455b-b68c-5c4e6d3cf521 (opens source in a new tab)
Lanthanum Carbonate label
Version not recorded · Effective date not recorded
Lanthanum was cleared from plasma of patients undergoing dialysis with an elimination half-life of 53 hours following discontinuation of therapy.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bb263fe8-2bdf-4dba-807f-194f54a73654 (opens source in a new tab)
Lanthanum Carbonate label
Version not recorded · Effective date not recorded
Lanthanum was cleared from plasma of patients undergoing dialysis with an elimination half-life of 53 hours following discontinuation of therapy.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:16b0e6f5-4fc9-448c-994a-cb9dd8b03654 (opens source in a new tab)
Lanthanum Carbonate label
Version not recorded · Effective date not recorded
Lanthanum was cleared from plasma of patients undergoing dialysis with an elimination half-life of 53 hours following discontinuation of therapy.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f10776b2-2c25-4343-aabe-68f302e5cb54 (opens source in a new tab)
Lanthanum Carbonate label
Version not recorded · Effective date not recorded
Lanthanum was cleared from plasma of patients undergoing dialysis with an elimination half-life of 53 hours following discontinuation of therapy.
Projected row 827
- Medicine slug
- larotrectinib
- Compared field
- bioavailability
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 2
- Source count
- 2
- Agreement rate
- 1
- Recorded readings
34%
- Numeric value
- 34
- Unit
- %
- Source records
- 2
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 2 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0c8ca614-58b2-4aa4-83d3-0387a8f782fd (opens source in a new tab)
Larotrectinib label
Version not recorded · Effective date not recorded
Absorption The mean absolute bioavailability of VITRAKVI capsules was 34% (range: 32% to 37%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9525f887-a055-4e33-8e92-898d42828cd1 (opens source in a new tab)
Larotrectinib label
Version not recorded · Effective date not recorded
Absorption The mean absolute bioavailability of VITRAKVI capsules was 34% (range: 32% to 37%).
Projected row 828
- Medicine slug
- larotrectinib
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 2
- Source count
- 2
- Agreement rate
- 1
- Recorded readings
2.9 hours
- Numeric value
- 2.9
- Unit
- hours
- Source records
- 2
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 2 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0c8ca614-58b2-4aa4-83d3-0387a8f782fd (opens source in a new tab)
Larotrectinib label
Version not recorded · Effective date not recorded
Elimination The mean (CV%) clearance (CL/F) of larotrectinib is 98 (44%) L/h and the half-life is 2.9 hours following oral administration of VITRAKVI in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9525f887-a055-4e33-8e92-898d42828cd1 (opens source in a new tab)
Larotrectinib label
Version not recorded · Effective date not recorded
Elimination The mean (CV%) clearance (CL/F) of larotrectinib is 98 (44%) L/h and the half-life is 2.9 hours following oral administration of VITRAKVI in healthy subjects.
Projected row 829
- Medicine slug
- latanoprost
- Compared field
- tMax
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 17
- Source count
- 5
- Agreement rate
- 1
- Recorded readings
2 hours
- Numeric value
- 2
- Unit
- hours
- Source records
- 5
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 5 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:34ad5cf6-4df0-4104-bddd-4c7631133ded (opens source in a new tab)
Latanoprost label
Version not recorded · Effective date not recorded
Studies in man indicate that the peak concentration in the aqueous humor is reached about 2 hours after topical administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:463ecfde-5acb-4983-969d-0c0021bfbf48 (opens source in a new tab)
Latanoprost label
Version not recorded · Effective date not recorded
Studies in man indicate that the peak concentration in the aqueous humor is reached about 2 hours after topical administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5d0b99ad-f05a-44c7-ac61-26b5a533ea8d (opens source in a new tab)
Latanoprost label
Version not recorded · Effective date not recorded
Studies in man indicate that the peak concentration in the aqueous humor is reached about 2 hours after topical administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a98595b3-9f47-48e0-b18d-550a2095f264 (opens source in a new tab)
Latanoprost label
Version not recorded · Effective date not recorded
Studies in man indicate that the peak concentration in the aqueous humor is reached about 2 hours after topical administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:be74d517-7f73-a74c-e053-2a95a90a3819 (opens source in a new tab)
Latanoprost label
Version not recorded · Effective date not recorded
Studies in man indicate that the peak concentration in the aqueous humor is reached about 2 hours after topical administration.
Projected row 830
- Medicine slug
- leflunomide
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 25
- Source count
- 25
- Agreement rate
- 1
- Recorded readings
18 to 19 days
- Numeric value
- Not parsed
- Unit
- Not recorded
- Source records
- 25
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 25 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c288d1d3-3fbe-4c34-a28a-923d515809b3 (opens source in a new tab)
Leflunomide label
Version not recorded · Effective date not recorded
Due to the very long half-life of teriflunomide (18 to 19 days), a loading dose of 100 mg for 3 days was used in clinical studies to facilitate the rapid attainment of steady-state teriflunomide concentrations.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d6f5c510-9ec2-4e2d-b134-25c35bd23fee (opens source in a new tab)
Leflunomide label
Version not recorded · Effective date not recorded
Due to the very long half-life of teriflunomide (18 to 19 days), a loading dose of 100 mg for 3 days was used in clinical studies to facilitate the rapid attainment of steady-state teriflunomide concentrations.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:af836cd0-da42-772e-e053-2995a90ac103 (opens source in a new tab)
Leflunomide label
Version not recorded · Effective date not recorded
Due to the very long half-life of teriflunomide (18 to 19 days), a loading dose of 100 mg for 3 days was used in clinical studies to facilitate the rapid attainment of steady-state teriflunomide concentrations.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:753453c5-8a7a-878e-3ce7-1d1edce718a9 (opens source in a new tab)
Leflunomide label
Version not recorded · Effective date not recorded
Due to the very long half-life of teriflunomide (18 to 19 days), a loading dose of 100 mg for 3 days was used in clinical studies to facilitate the rapid attainment of steady-state teriflunomide concentrations.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:320f63f2-fac3-4aee-aff8-85724e00ef52 (opens source in a new tab)
Leflunomide label
Version not recorded · Effective date not recorded
Due to the very long half-life of teriflunomide (18–19 days), a loading dose of 100 mg for 3 days was used in clinical studies to facilitate the rapid attainment of steady-state teriflunomide concentrations.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a48e6ef2-48ad-4fcf-9e67-dbba83ab0b79 (opens source in a new tab)
Leflunomide label
Version not recorded · Effective date not recorded
Due to the very long half-life of teriflunomide (18-19 days), a loading dose of 100 mg for 3 days was used in clinical studies to facilitate the rapid attainment of steady-state teriflunomide concentrations.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b9af9870-014f-4c4e-8738-bb04b30b3e85 (opens source in a new tab)
Leflunomide label
Version not recorded · Effective date not recorded
Due to the very long half-life of teriflunomide (18 to 19 days), a loading dose of 100 mg for 3 days was used in clinical studies to facilitate the rapid attainment of steady-state teriflunomide concentrations.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:acf3efe4-0d70-4718-9c50-789d69ab215d (opens source in a new tab)
Leflunomide label
Version not recorded · Effective date not recorded
Due to the very long half-life of teriflunomide (18 to 19 days), a loading dose of 100 mg for 3 days was used in clinical studies to facilitate the rapid attainment of steady-state teriflunomide concentrations.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:91712aad-d96c-4ef0-97e7-b31ed18ca6d8 (opens source in a new tab)
Leflunomide label
Version not recorded · Effective date not recorded
Due to the very long half-life of teriflunomide (18 to 19 days), a loading dose of 100 mg for 3 days was used in clinical studies to facilitate the rapid attainment of steady-state teriflunomide concentrations.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fa5f71b3-6a56-4616-baf7-4b761023b2a9 (opens source in a new tab)
Leflunomide label
Version not recorded · Effective date not recorded
Due to the very long half-life of teriflunomide (18 to 19 days), a loading dose of 100 mg for 3 days was used in clinical studies to facilitate the rapid attainment of steady-state teriflunomide concentrations.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8b365514-c859-ff93-e053-2a95a90ac698 (opens source in a new tab)
Leflunomide label
Version not recorded · Effective date not recorded
Due to the very long half-life of teriflunomide (18 to 19 days), a loading dose of 100 mg for 3 days was used in clinical studies to facilitate the rapid attainment of steady-state teriflunomide concentrations.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f6a4107e-b393-45ed-8e5a-70af5bd53826 (opens source in a new tab)
Leflunomide label
Version not recorded · Effective date not recorded
Due to the very long half-life of teriflunomide (18 to 19 days), a loading dose of 100 mg for 3 days was used in clinical studies to facilitate the rapid attainment of steady-state teriflunomide concentrations.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c358276a-610e-46da-b81a-95c837af205d (opens source in a new tab)
Leflunomide label
Version not recorded · Effective date not recorded
Due to the very long half-life of teriflunomide (18 to 19 days), a loading dose of 100 mg for 3 days was used in clinical studies to facilitate the rapid attainment of steady-state teriflunomide concentrations.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:af4079af-c127-476e-a2b3-53b438dc9da4 (opens source in a new tab)
Leflunomide label
Version not recorded · Effective date not recorded
Due to the very long half-life of teriflunomide (18 to 19 days), a loading dose of 100 mg for 3 days was used in clinical studies to facilitate the rapid attainment of steady-state teriflunomide concentrations.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0a4f8671-b632-4cc5-8dc9-6b863e62b467 (opens source in a new tab)
Leflunomide label
Version not recorded · Effective date not recorded
Due to the very long half-life of teriflunomide (18 to 19 days), a loading dose of 100 mg for 3 days was used in clinical studies to facilitate the rapid attainment of steady-state teriflunomide concentrations.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:006b5bf4-97c0-48dc-8e5e-3c6f64d7bdc1 (opens source in a new tab)
Leflunomide label
Version not recorded · Effective date not recorded
Due to the very long half-life of teriflunomide (18 to 19 days), a loading dose of 100 mg for 3 days was used in clinical studies to facilitate the rapid attainment of steady-state teriflunomide concentrations.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:40dd071a-d07f-452f-bf1a-2a23b9d22ca4 (opens source in a new tab)
Leflunomide label
Version not recorded · Effective date not recorded
Due to the very long half-life of teriflunomide (18 to 19 days), a loading dose of 100 mg for 3 days was used in clinical studies to facilitate the rapid attainment of steady-state teriflunomide concentrations.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fc044417-cd9a-42f6-8a3d-a14e7c2f81a2 (opens source in a new tab)
Leflunomide label
Version not recorded · Effective date not recorded
Due to the very long half-life of teriflunomide (18–19 days), a loading dose of 100 mg for 3 days was used in clinical studies to facilitate the rapid attainment of steady-state teriflunomide concentrations.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c66cacd1-93f7-483a-a2fc-aad53d5342b0 (opens source in a new tab)
Leflunomide label
Version not recorded · Effective date not recorded
Due to the very long half-life of teriflunomide (18 to 19 days), a loading dose of 100 mg for 3 days was used in clinical studies to facilitate the rapid attainment of steady-state teriflunomide concentrations.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2b5c98d0-de59-85f6-e063-6394a90ab67a (opens source in a new tab)
Leflunomide label
Version not recorded · Effective date not recorded
Due to the very long half-life of teriflunomide (18 to 19 days), a loading dose of 100 mg for 3 days was used in clinical studies to facilitate the rapid attainment of steady-state teriflunomide concentrations.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d0fb9685-9e54-44e5-b543-1077e1a620c6 (opens source in a new tab)
Leflunomide label
Version not recorded · Effective date not recorded
Due to the very long half-life of teriflunomide (18 to 19 days), a loading dose of 100 mg for 3 days was used in clinical studies to facilitate the rapid attainment of steady-state teriflunomide concentrations.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e76d7767-744f-4e52-956d-e59f7a924826 (opens source in a new tab)
Leflunomide label
Version not recorded · Effective date not recorded
Due to the very long half-life of teriflunomide (18 to 19 days), a loading dose of 100 mg for 3 days was used in clinical studies to facilitate the rapid attainment of steady-state teriflunomide concentrations.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2b5f387e-b52b-ad80-e063-6394a90a56d5 (opens source in a new tab)
Leflunomide label
Version not recorded · Effective date not recorded
Due to the very long half-life of teriflunomide (18 to 19 days), a loading dose of 100 mg for 3 days was used in clinical studies to facilitate the rapid attainment of steady-state teriflunomide concentrations.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e85c4eed-794c-409b-aed5-3c857b14b1fb (opens source in a new tab)
Leflunomide label
Version not recorded · Effective date not recorded
Due to the very long half-life of teriflunomide (18 to 19 days), a loading dose of 100 mg for 3 days was used in clinical studies to facilitate the rapid attainment of steady-state teriflunomide concentrations.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5d48fded-b43b-461a-8488-ca1da5c41a03 (opens source in a new tab)
Leflunomide label
Version not recorded · Effective date not recorded
Due to the very long half-life of teriflunomide (18 to 19 days), a loading dose of 100 mg for 3 days was used in clinical studies to facilitate the rapid attainment of steady-state teriflunomide concentrations.
Access
Query or download the projection
GET /api/datasets/source-consensus?limit=10&offset=820Allowed query parameters
- q
- Case-insensitive text search over the public fields named for this dataset.
- state
- Exact comparability state.Values: agree, differ, not_comparable, insufficient_context
- field
- Exact recorded field key.Values: bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
- limit / offset
- Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.
Reuse and corrections
Keep the boundary attached
CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.
Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.